The public defence will be held as a video conference over Zoom.
The defence will follow regular procedure as far as possible, hence it will be open to the public and the audience can ask ex auditorio questions when invited to do so.
Click here to participate in the public defence
Digital trial lecture - time and place
Adjudication committee
- First opponent: Professor Suzanne Marie Garland, University of Melbourne Medical School, Australia
- Second opponent: Group Head Gary Clifford, International Agency for Research on Cancer, World Health Organization, Lyon, France
- Third member and chair of the evaluation committee: Associate Professor Tone Kristin Omsland, Institute of Health and Society, University of Oslo
Chair of defence
Professor Emeritus Per Nafstad, Institute of Health and Society, University of Oslo
Principal supervisor
Mari Nygård, Cancer Registry of Norway, Oslo
Summary
Infection with human papillomavirus (HPV) is very common, and there are hundreds of different HPV types. The majority of these types are harmless and may cause warts on hands, feet, and genitals, while some types may cause cancer after persistent infection. Increasing trends in the incidence of cervical precancer and HPV-related cancer have been attributed to increasing exposure to HPV in the population. Vaccines against HPV infection which may cause cancer or genital warts have been available for more than ten years and they have shown high effectiveness against persistent HPV infection, cervical precancer and genital warts.
The data analyzed in this thesis was obtained from eight Norwegian and four Danish high-quality population-based registries. The overall aim of this thesis was to investigate temporal trends in the epidemiology of three HPV-related diseases (cervical precancer, penile cancer, and genital warts) in Norway. In addition, the impact of HPV multi-cohort vaccination was investigated by comparing incidence trends of genital warts between Norway and Denmark.
Additional information
contact the Research Support staff